Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients
4 other identifiers
observational
26
1 country
1
Brief Summary
The aim of our study is to determine whether a clinically relevant laboratory measurement (of seven specific immunologic biochemicals in the blood) can identify which bone marrow transplant recipients are likely to progress to respiratory failure. Our ultimate goal is to devise a comprehensive and inclusive laboratory test that is effective at determining who is likely to go on to respiratory failure, in order to facilitate early medical intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedFirst Submitted
Initial submission to the registry
June 1, 2010
CompletedFirst Posted
Study publicly available on registry
June 2, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2011
CompletedJune 21, 2024
June 1, 2024
2.4 years
June 1, 2010
June 18, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Compute median flourescence intensity, standard curves, and estimated pg/mL for each cytokine.
weekly during hospitalization for transplant
Eligibility Criteria
Hematopoietic stem cell transplantation (HSCT) for any indication.
You may qualify if:
- Patients will range from age 0 to age 21. There is no gender restriction. We expect the male to female ratio to end up being about 50/50
- Ability to understand and the willingness to sign a written informed consent document.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford University School of Medicine
Stanford, California, 94305, United States
Biospecimen
blood
Study Officials
- PRINCIPAL INVESTIGATOR
Rajni Agarwal-Hashmi
Stanford University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Pediatrics
Study Record Dates
First Submitted
June 1, 2010
First Posted
June 2, 2010
Study Start
July 1, 2008
Primary Completion
December 1, 2010
Study Completion
January 1, 2011
Last Updated
June 21, 2024
Record last verified: 2024-06